Lantheus Holdings Inc
LNTH73.995USD
-0.415-0.56%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
5.12BMarktkapitalisierung
20.12KGV TTM
mehr Informationen über Lantheus Holdings Inc Unternehmen
Lantheus Holdings, Inc. is a radiopharmaceutical-focused company engaged in delivering science to enable clinicians to find, fight and follow diseases to deliver patient outcomes. It classifies its products in three categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships. Radiopharmaceutical Oncology diagnostics and therapeutics help healthcare professionals (HCPs) find, fight and follow cancer, with a focus on prostate cancer. Precision Diagnostic products assist HCPs to find and follow diseases, with a focus on cardiology. Strategic Partnerships focus on enabling precision medicine through the use of biomarker solutions, digital solutions, and radiotherapeutic platforms. Its commercial products include PYLARIFY, DEFINITY, TechneLite, and others. Its clinical candidates include LNTH-2404, NAV-4694, and PNT2002, others. Its OCTEVY is a registrational-stage positron emission tomography (PET) diagnostic imaging agent targeting neuroendocrine tumors.
Unternehmensinformationen
BörsenkürzelLNTH
Name des UnternehmensLantheus Holdings Inc
IPO-datumJun 25, 2015
Gegründet am2007
CEOMr. Brian A. Markison
Anzahl der mitarbeiter808
WertpapierartOrdinary Share
GeschäftsjahresendeJun 25
Addresse331 Treble Cove Road
StadtNORTH BILLERICA
BörseNASDAQ Global Market Consolidated
LandUnited States of America
Postleitzahl01862
Telefon19786718001
Websitehttps://www.lantheus.com/
BörsenkürzelLNTH
IPO-datumJun 25, 2015
Gegründet am2007
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Ms. Mary Anne Heino
Ms. Mary Anne Heino
Chairman of the Board
Chairman of the Board
584.72K
-4.27%
Mr. Brian A. Markison
Mr. Brian A. Markison
Chief Executive Officer, Director
Chief Executive Officer, Director
232.42K
+35.31%
Ms. Amanda Morgan
Ms. Amanda Morgan
Chief Commercial Officer
Chief Commercial Officer
39.58K
+55.76%
Dr. Jean-Claude Provost, M.D.
Dr. Jean-Claude Provost, M.D.
Chief Scientific Officer
Chief Scientific Officer
38.84K
-31.55%
Dr. James H. (Jim) Thrall
Dr. James H. (Jim) Thrall
Independent Director
Independent Director
35.74K
+7.64%
Ms. Julie H. Mchugh
Ms. Julie H. Mchugh
Lead Independent Director
Lead Independent Director
25.96K
-16.67%
Dr. Gerard Ber, Ph.D.
Dr. Gerard Ber, Ph.D.
Independent Director
Independent Director
23.36K
+10.09%
Ms. Minnie Baylor-Henry, J.D.
Ms. Minnie Baylor-Henry, J.D.
Independent Director
Independent Director
9.90K
+34.47%
Dr. Phuong Khanh (P. K.) Morrow, M.D.
Dr. Phuong Khanh (P. K.) Morrow, M.D.
Independent Director
Independent Director
3.10K
+450.62%
Mr. Samuel R. (Sam) Leno
Mr. Samuel R. (Sam) Leno
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Ms. Mary Anne Heino
Ms. Mary Anne Heino
Chairman of the Board
Chairman of the Board
584.72K
-4.27%
Mr. Brian A. Markison
Mr. Brian A. Markison
Chief Executive Officer, Director
Chief Executive Officer, Director
232.42K
+35.31%
Ms. Amanda Morgan
Ms. Amanda Morgan
Chief Commercial Officer
Chief Commercial Officer
39.58K
+55.76%
Dr. Jean-Claude Provost, M.D.
Dr. Jean-Claude Provost, M.D.
Chief Scientific Officer
Chief Scientific Officer
38.84K
-31.55%
Dr. James H. (Jim) Thrall
Dr. James H. (Jim) Thrall
Independent Director
Independent Director
35.74K
+7.64%
Ms. Julie H. Mchugh
Ms. Julie H. Mchugh
Lead Independent Director
Lead Independent Director
25.96K
-16.67%
Umsatzaufteilung
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
PYLARIFY
257.65M
0.00%
DEFINITY
79.21M
0.00%
TechneLite
19.71M
0.00%
Strategic partnerships and other
10.75M
0.00%
Other precision diagnostics
5.44M
0.00%
Radiopharmaceutical oncology
0.00
0.00%
Keine Daten
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
PYLARIFY
257.65M
0.00%
DEFINITY
79.21M
0.00%
TechneLite
19.71M
0.00%
Strategic partnerships and other
10.75M
0.00%
Other precision diagnostics
5.44M
0.00%
Radiopharmaceutical oncology
0.00
0.00%
Aktionärsstatistik
Aktualisiert: Wed, May 14
Aktualisiert: Wed, May 14
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
BlackRock Institutional Trust Company, N.A.
11.27%
The Vanguard Group, Inc.
10.10%
Janus Henderson Investors
9.05%
Farallon Capital Management, L.L.C.
8.71%
State Street Global Advisors (US)
3.81%
Other
57.07%
Aktionäre
Aktionäre
Anteil
BlackRock Institutional Trust Company, N.A.
11.27%
The Vanguard Group, Inc.
10.10%
Janus Henderson Investors
9.05%
Farallon Capital Management, L.L.C.
8.71%
State Street Global Advisors (US)
3.81%
Other
57.07%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor/Hedge Fund
53.47%
Investment Advisor
43.79%
Hedge Fund
11.55%
Research Firm
3.19%
Individual Investor
2.27%
Pension Fund
1.94%
Bank and Trust
1.35%
Sovereign Wealth Fund
0.57%
Family Office
0.09%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
1027
81.92M
118.40%
-3.35M
2025Q1
1066
83.20M
120.27%
-2.89M
2024Q4
1033
78.65M
114.86%
-4.64M
2024Q3
1003
73.69M
106.06%
-7.92M
2024Q2
959
71.82M
103.63%
-10.29M
2024Q1
912
71.21M
103.87%
-11.25M
2023Q4
868
73.50M
107.32%
-9.24M
2023Q3
828
74.80M
109.31%
-3.81M
2023Q2
790
72.85M
106.61%
-3.94M
2023Q1
733
71.94M
105.47%
-6.73M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
BlackRock Institutional Trust Company, N.A.
7.79M
11.27%
+17.69K
+0.23%
Mar 31, 2025
The Vanguard Group, Inc.
6.99M
10.1%
-242.63K
-3.36%
Mar 31, 2025
Janus Henderson Investors
6.26M
9.05%
-252.58K
-3.88%
May 30, 2025
Farallon Capital Management, L.L.C.
6.02M
8.71%
+707.00K
+13.30%
Mar 31, 2025
State Street Global Advisors (US)
2.64M
3.81%
-4.26K
-0.16%
Mar 31, 2025
Fidelity Management & Research Company LLC
2.17M
3.14%
+148.84K
+7.36%
Mar 31, 2025
Geode Capital Management, L.L.C.
1.78M
2.57%
+94.57K
+5.62%
Mar 31, 2025
Westfield Capital Management Company, L.P.
1.59M
2.3%
+34.05K
+2.19%
Mar 31, 2025
T. Rowe Price Investment Management, Inc.
1.41M
2.04%
-96.91K
-6.42%
Mar 31, 2025
Reinhart Partners, LLC
1.21M
1.74%
-160.93K
-11.77%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sun, Jul 6
Aktualisiert: Sun, Jul 6
Name
Anteil
Harbor Health Care ETF
2.88%
Invesco S&P MidCap 400 GARP ETF
2.64%
Invesco Dorsey Wright Healthcare Momentum ETF
2.28%
SPDR S&P Health Care Equipment ETF
1.83%
Fidelity Stocks for Inflation ETF
1.32%
Janus Henderson US Sustainable Equity ETF
1.26%
Invesco S&P MidCap 400 Pure Growth ETF
1.06%
First Trust Small Cap US Equity Select ETF
1%
Astoria US Quality Kings ETF
0.78%
VictoryShares Free Cash Flow Growth ETF
0.74%
Mehr Anzeigen
Harbor Health Care ETF
Anteil2.88%
Invesco S&P MidCap 400 GARP ETF
Anteil2.64%
Invesco Dorsey Wright Healthcare Momentum ETF
Anteil2.28%
SPDR S&P Health Care Equipment ETF
Anteil1.83%
Fidelity Stocks for Inflation ETF
Anteil1.32%
Janus Henderson US Sustainable Equity ETF
Anteil1.26%
Invesco S&P MidCap 400 Pure Growth ETF
Anteil1.06%
First Trust Small Cap US Equity Select ETF
Anteil1%
Astoria US Quality Kings ETF
Anteil0.78%
VictoryShares Free Cash Flow Growth ETF
Anteil0.74%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
